2022年ASCO转移性乳腺癌的治疗进展

贾勇圣; 佟仲生

doi:10.12354/j.issn.1000-8179.2023.20220959

2022年ASCO转移性乳腺癌的治疗进展

doi: 10.12354/j.issn.1000-8179.2023.20220959

贾勇圣,
佟仲生^,

天津医科大学肿瘤医院乳腺肿瘤内科，国家恶性肿瘤临床医学研究中心，天津市"肿瘤防治"重点实验室，天津市恶性肿瘤临床医学研究中心，乳腺癌防治教育部重点实验室（天津市300060）

详细信息

作者简介:
贾勇圣：专业方向为乳腺癌免疫治疗及乳腺癌细胞转移机制与影响因素的研究

通讯作者:
佟仲生　18622221181@163.com

计量
- 文章访问数: 125
- HTML全文浏览量: 32
- PDF下载量: 83
- 被引次数: 0
出版历程
- 收稿日期: 2022-06-23
- 录用日期: 2022-12-01
- 修回日期: 2022-11-22

Progress in the treatment of metastatic breast cancer at the ASCO 2022

Yongsheng Jia,
Zhongsheng Tong^,

Department of Breast Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy (Ministry of Education), Tianjin 300060, China

More Information

Corresponding author: Zhongsheng Tong; E-mail: 18622221181@163.com

摘要

摘要: 美国临床肿瘤学会（ASCO）2022年会的乳腺癌研究首次证实HER-2靶向治疗可改善HER-2低表达患者的生存预后，HR阳性/HER-2阴性转移性乳腺癌患者使用戈沙妥珠单抗后延长无进展生存期，驱动基因HER-3成为乳腺癌治疗的新靶点，哌柏西利联合来曲唑一线治疗的总生存结果为阴性，HR阳性/HER-2阴性转移性乳腺癌标准治疗进展后更换内分泌药物并持续CDK4/6抑制剂治疗仍可延长患者无进展生存期。本文将就此次大会中有关转移性乳腺癌治疗的重要进展进行综述。
- 乳腺癌 /
- HER-2 /
- 靶向治疗
Abstract: Breast cancer studies presented at the 2022 ASCO meeting demonstrated several novel findings: improved survival prognosis in patients with low HER-2 expression with HER-2-targeted therapy, prolonged progression-free survival (PFS) with sacituzumab govitecan in patients with HR-positive/HER-2-negative metastatic breast cancer, oncodriver gene HER-3 as a new target for breast cancer treatment, negative overall survival outcomes with palbociclib combined with letrozole as the first-line treatment, hormone replacement therapy, and further improvement in PFS with continued CDK4/6 inhibitor therapy after progression of standard therapy in HR-positive/HER-2-negative metastatic breast cancer. This article reviews important advances in the treatment of metastatic breast cancer from this conference.
- breast cancer /
- HER-2 /
- targeted therapy

HTML全文

参考文献(18)

[1]	Modi SN, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): results of DESTINY-Breast04, a randomized, phase 3 study[J]. J Clin Oncol, 2022, 40(17_Suppl):LBA3. doi: 10.1200/JCO.2022.40.17_suppl.LBA3
[2]	Hamilton EP, Bragaia VPH, Yeo W, et al. Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): safety follow-up of the randomized, phase 3 study DESTINY-Breast03[J]. J Clin Oncol, 2022, 40(16_Suppl):1000. doi: 10.1200/JCO.2022.40.16_suppl.1000
[3]	Kish JK, Mehta S, Kwong J, et al. Monitoring and management of interstitial lung disease/pneumonitis among patients with metastatic breast cancer treated with trastuzumab deruxtecan[J]. J Clin Oncol, 2022, 40(16_Suppl):1036. doi: 10.1200/JCO.2022.40.16_suppl.1036
[4]	Lee KS, Wang XJ, Im YH, et al. Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: preliminary results from a phase 1b/2 study[J]. J Clin Oncol, 2022, 40(16_Suppl):1031. doi: 10.1200/JCO.2022.40.16_suppl.1031
[5]	Hao CF, Wang X, Shi YH, et al. Pyrotinib in combination with metronomic oral vinorelbine in patients with HER2-positive advanced breast cancer who had failed prior trastuzumab-based therapy: a single-center, single-arm, prospective phase 2 study[J]. J Clin Oncol, 2022, 40(16_Suppl):1033. doi: 10.1200/JCO.2022.40.16_suppl.1033
[6]	Guan XW, Ma F, Li Q, et al. Pyrotinib monotherapy or pyrotinib in combination with capecitabine could significantly prolong progression-free survival and overall survival in patients with HER2-positive metastatic breast cancer[J]. J Clin Oncol, 2022, 40(16_Suppl):1034. doi: 10.1200/JCO.2022.40.16_suppl.1034
[7]	Li H, Li ZH, Yan M, et al. Pyrotinib plus nab-paclitaxel in patients with HER2-positive advanced or metastatic breast cancer: a multicenter, single-arm, open-label phase 2 trial[J]. J Clin Oncol, 2022, 40(16_Suppl):1035. doi: 10.1200/JCO.2022.40.16_suppl.1035
[8]	Rugo HS, Bardia A, Marmé F, et al. Primary results from TROPiCS-02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (Pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer[J]. J Clin Oncol, 2022, 40(17_Suppl):LBA1001. doi: 10.1200/JCO.2022.40.17_suppl.LBA1001
[9]	Finn RS, Rugo HS, Dieras VC, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ER+/HER2–ABC): analyses from PALOMA-2[J]. J Clin Oncol, 2022, 40(17_Suppl):LBA1003. doi: 10.1200/JCO.2022.40.17_suppl.LBA1003
[10]	Kalinsky K, Accordino MK, Chiuzan C, et al. A randomized, phase Ⅱ trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC): maintain trial[J]. J Clin Oncol, 2022, 40(17_suppl):LBA1004.
[11]	Rugo HS, O'Shaughnessy J, Jhaveri KL, et al. Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC)[J]. J Clin Oncol, 2022, 40(16_suppl):1015.
[12]	Hart LL, Bardia A, Beck JT, et al. Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+/HER2- advanced breast cancer (ABC) in MONALEESA(ML)-2[J]. J Clin Oncol, 2022, 40(16_Suppl):1017. doi: 10.1200/JCO.2022.40.16_suppl.1017
[13]	Damodaran S, Plourde PV, Moore HCF, et al. Open-label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre- and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer and an ESR1 mutation after progression on prior therapies[J]. J Clin Oncol, 2022, 40(16_Suppl):1022. doi: 10.1200/JCO.2022.40.16_suppl.1022
[14]	Jones RH, Casbard AC, Carucci M, et al. Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor-positive breast cancer (FAKTION): overall survival and updated progression-free survival data with enhanced biomarker analysis[J]. J Clin Oncol, 2022, 40(16_Suppl):1005. doi: 10.1200/JCO.2022.40.16_suppl.1005
[15]	Juric D, Rugo HS, Chia SKL, et al. Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC): baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study[J]. J Clin Oncol, 2022, 40(16_Suppl):1018. doi: 10.1200/JCO.2022.40.16_suppl.1018
[16]	Wander SA, Weipert C, Liao JM, et al. Use of real-world data (RWD) to assess the utility of cell-free circulating tumor DNA (cfDNA) in identifying resistance to early treatment in advanced breast cancer (aBC)[J]. J Clin Oncol, 2022, 40(16_Suppl):1011. doi: 10.1200/JCO.2022.40.16_suppl.1011
[17]	Krop IE, Masuda N, Mukohara T, et al. Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)[J]. J Clin Oncol, 2022, 40(16_Suppl):1002. doi: 10.1200/JCO.2022.40.16_suppl.1002
[18]	Cao MR, Lu HL, Yan S, et al. Apatinib plus etoposide as second-or higher-line treatment in recurrent or metastatic triple-negative breast cancer: a single-arm, open label, prospective, phase Ⅱ clinical trial[J]. J Clin Oncol, 2022, 40(16_Suppl):e13069. doi: 10.1200/JCO.2022.40.16_suppl.e13069